Study Reveals Importance Of Timing For Cellular Signals, Suggests Possible Tactic For Cancer Therapeutics
Magic tricks work because they take advantage of the brain’s sensory assumptions, tricking audiences into seeing phantoms or overlooking sleights of hand. Now a team of UC San Francisco researchers has discovered that even brainless single-celled yeast have sensory biases that can be hacked by a carefully engineered illusion, a finding that could be used to develop new approaches to fighting diseases such as cancer.
“The ability to perceive and respond to the environment is a basic attribute of all living organisms, from the greatest to the smallest,” said Wendell Lim, PhD, the study’s senior author. “And so is the susceptibility to misperception. It doesn’t matter if the illusion is based on molecular sensors within a single cell or neurons in the brain.”
In the new study, published online Nov. 19, 2015 in Science Express, Lim and his team discovered that yeast cells falsely perceive a specifically timed pattern of stress – caused by alternating between low and mildly increased sodium levels – as a massive, continuously increasing ramp of stress. In response, the microbes end up over-responding and killing themselves. The results, Lim says, suggest a whole new way of looking at the perceptual abilities of simple cells and could even be used to develop new approaches to fighting diseases using the power of illusion.
Timing of stress response is yeast cells’ ‘Achilles heel’
“This discovery was a bit of an accident actually,” said Lim, chair of the Department of Cellular and Molecular Pharmacology at UCSF, director of the UCSF Center for Systems and Synthetic Biology, and a Howard Hughes Medical Institute (HHMI) investigator. “We were interested in the general issue of how cells interpret information over time. Frequency is a key aspect of all our communications, whether it’s hearing language or transmitting radio signals, but do cells themselves use this kind of information? It’s something we don’t know much about.”
To explore this question, two postdoctoral fellows in Lim’s lab, Ping Wei, PhD, now at Peking University School of Life Sciences, and Amir Mitchell, PhD, set up a system that allowed them to expose yeast to a mild stressor – a small increase in salt in the yeast’s environment – and to oscillate between the increased salt level and the baseline level at different frequencies.
Normally, sensor molecules in a yeast cell detect changes in salt concentration and instruct the cell to respond by producing a protective chemical. After this transient response, the cell can resume growing happily as if conditions had not changed. The researchers found that the cells were perfectly capable of adapting when they flipped the salt stress on and off every minute or every 32 minutes. But to their surprise, when they tried an eight-minute oscillation of precisely the same salt level the cells quickly stopped growing and began to die off.
“That was just a jaw-dropping moment,” said Mitchell. “These cells should be able to handle this level of osmotic stress, but at one particular frequency they just go haywire. We’d never seen anything like this before.”
Could sensory illusions be used to fight cancer?
Mitchell, who was first author on the new study, went on to inspect the cellular mechanism underlying this unexpected, frequency-dependent toxicity. Using mathematical modeling and experiments in which he tweaked the molecular wiring of the mitogen activated protein kinase (MAPK) pathway that mediates the cells’ salt-sensing system, he revealed a sensory misperception: Because of the way the MAPK pathway is set up, the cells interpret an eight-minute oscillation as an ever-increasing staircase of salt concentration. This leads to excessive activation of the cells’ protective response, and ultimately to their death (see Movie).
The Latest on: Cancer Therapeutics
[google_news title=”” keyword=”Cancer Therapeutics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer Therapeutics
- Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Dataon November 18, 2022 at 9:10 am
Monopar Therapeutics MNPR shares increased 7.25% on Nov 17, after the company reported data from its ongoing soft-tissue sarcoma study on Nov 16. The company provided data from its phase Ib study ...
- Lab Notes: Fox Chase Cancer Center enters Pfizer genomic disparities collaboration; Avstera Therapeutics raises $4.55Mon November 18, 2022 at 7:51 am
Fox Chase Cancer Center has entered into a collaboration to study genomic disparities in African ancestry populations, Avstera Therapeutics raises seed funding, and more life sciences news.
- Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meetingon November 18, 2022 at 5:43 am
VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program The third poster presented information on fourteen patients with recurrent GBM who were treated at MD Anderson ...
- Regeneron, CytomX announce bispecific therapeutics for cancer collabon November 18, 2022 at 3:56 am
Regeneron and CytomX have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics ...
- ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Canceron November 17, 2022 at 9:17 am
HOUSTON, November 17, 2022--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today ...
- Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?on November 17, 2022 at 7:47 am
CytomX Therapeutics (NASDAQ:CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ:REGN). Load Error This ...
- Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Canceron November 17, 2022 at 4:20 am
Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody® and Regeneron's ...
- Bladder Cancer Therapeutics Market Is Anticipated To Register Around 6.4% CAGR From 2022-2031on November 17, 2022 at 1:17 am
The Bladder Cancer Therapeutics market is expected to grow significantly in the next decade. The number of new cases diagnosed yearly is expected to increase as the population ages. The most common ...
- Non-small Cell Lung Cancer Therapeutics Market Outlook: Expecting an Outstanding Growth of 6.3% CAGR, Current Trends, Share, and Forecast till 2028on November 17, 2022 at 12:15 am
Nov (The Expresswire) -- "Final Report will add the analysis of the COVID-19 and Russia Ukraine war impact on this industry." Report on ...
- Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Studyon November 16, 2022 at 7:09 am
Monopar Therapeutics Inc (NASDAQ: MNPR) released data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients. The prior exploratory clinical ...
via Bing News